Table 5 Univariate Cox regression analysis of the impact of lncRNA signature and other clinicopathological features on DFS in the three NSCLC patient cohorts
Parameters | Training group | Validation group | Independent group | |||
|---|---|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
Signature | ||||||
 (High vs low) | 2.61 (1.50–4.56) | < 0.001 | 3.21 (1.80–5.71) | < 0.001 | 2.18 (1.10–4.34) | 0.025 |
Age | ||||||
 (≥ 60 vs < 60) | 1.30 (0.76–2.21) | 0.330 | 1.30 (0.76–2.21) | 0.510 | 1.19 (0.60–2.35) | 0.599 |
Gender | ||||||
 (Male vs female) | 0.57 (0.33–1.00) | 0.050 | 0.97 (0.53–1.78) | 0.945 | 0.77 (0.37–1.60) | 0.496 |
TNM stages | ||||||
 (III vs II vs I) | 1.55 (1.18–2.04) | 0.001 | 1.70 (1.29–2.25) | < 0.001 | 1.46 (1.00–2.12) | 0.045 |
Histological type | ||||||
 (ADC vs SCC) | 0.83 (0.44–1.59) | 0.589 | 1.48 (0.88–2.49) | 0.133 | 1.02 (0.45–2.29) | 0.954 |
Tumor size | ||||||
 (≥ 5 cm vs < 5 cm) | 1.89 (1.12–3.22) | 0.017 | 1.57 (0.94–2.61) | 0.082 | 1.92 (0.92–4.03) | 0.081 |
Differentiation | ||||||
 (Poor vs well/moderate) | 0.62 (0.36–1.05) | 0.079 | 1.22 (0.73–2.04) | 0.427 | 1.29 (0.65–2.57) | 0.453 |
Lymph metastasis | ||||||
 (Yes vs no) | 1.82 (1.07–3.10) | 0.025 | 1.72 (1.01–2.91) | 0.042 | 2.13 (0.87–5.23) | 0.095 |
Smoking history | ||||||
 (Yes vs no) | 0.54 (0.32–0.92) | 0.024 | 1.15 (0.68–1.95) | 0.586 | 1.00 (0.51–1.97) | 0.989 |
Fam. cancer hist. | ||||||
 (Yes vs no) | 0.80 (0.38–1.71) | 0.580 | 0.69 (0.31–1.53) | 0.369 | 1.23 (0.16–9.12) | 0.834 |